BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35254415)

  • 1. Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung Cancer.
    Chiappori AA; Creelan B; Tanvetyanon T; Gray JE; Haura EB; Thapa R; Barlow ML; Chen Z; Chen DT; Beg AA; Boyle TA; Castro J; Morgan L; Morris E; Aregay M; Hurtado FK; Manenti L; Antonia S
    Clin Cancer Res; 2022 Jun; 28(11):2313-2320. PubMed ID: 35254415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies.
    Schöffski P; Tan DSW; Martín M; Ochoa-de-Olza M; Sarantopoulos J; Carvajal RD; Kyi C; Esaki T; Prawira A; Akerley W; De Braud F; Hui R; Zhang T; Soo RA; Maur M; Weickhardt A; Krauss J; Deschler-Baier B; Lau A; Samant TS; Longmire T; Chowdhury NR; Sabatos-Peyton CA; Patel N; Ramesh R; Hu T; Carion A; Gusenleitner D; Yerramilli-Rao P; Askoxylakis V; Kwak EL; Hong DS
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35217575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors.
    Bauer TM; Santoro A; Lin CC; Garrido-Laguna I; Joerger M; Greil R; Spreafico A; Yau T; Goebeler ME; Hütter-Krönke ML; Perotti A; Juif PE; Lu D; Barys L; Cremasco V; Pelletier M; Evans H; Fabre C; Doi T
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38030303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors.
    Leidner R; Conlon K; McNeel DG; Wang-Gillam A; Gupta S; Wesolowski R; Chaudhari M; Hassounah N; Lee JB; Ho Lee L; O'Keeffe JA; Lewis N; Pavlakis GN; Thompson JA
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37907221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas.
    Piha-Paul SA; Geva R; Tan TJ; Lim DW; Hierro C; Doi T; Rahma O; Lesokhin A; Luke JJ; Otero J; Nardi L; Singh A; Xyrafas A; Chen X; Mataraza J; Bedard PL
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34389618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors.
    Naing A; Gainor JF; Gelderblom H; Forde PM; Butler MO; Lin CC; Sharma S; Ochoa de Olza M; Varga A; Taylor M; Schellens JHM; Wu H; Sun H; Silva AP; Faris J; Mataraza J; Cameron S; Bauer TM
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32179633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations.
    Janku F; Kim TM; Iyer G; Spreafico A; Elez E; de Jonge M; Yamamoto N; van der Wekken AJ; Ascierto PA; Maur M; Marmé F; Kiladjian JJ; Basu S; Baffert F; Buigues A; Chen C; Cooke V; Giorgetti E; Kim J; McCarthy F; Moschetta M; Dummer R
    Eur J Cancer; 2024 Jan; 196():113458. PubMed ID: 38039779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase Ib/II trial of capmatinib plus spartalizumab
    Santoro A; Assenat E; Yau T; Delord JP; Maur M; Knox J; Cattan S; Lee KH; Del Conte G; Springfeld C; Leo E; Xyrafas A; Fairchild L; Mardjuadi F; Chan SL
    JHEP Rep; 2024 Apr; 6(4):101021. PubMed ID: 38617599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
    Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
    Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors.
    Curigliano G; Gelderblom H; Mach N; Doi T; Tai D; Forde PM; Sarantopoulos J; Bedard PL; Lin CC; Hodi FS; Wilgenhof S; Santoro A; Sabatos-Peyton CA; Longmire TA; Xyrafas A; Sun H; Gutzwiller S; Manenti L; Naing A
    Clin Cancer Res; 2021 Jul; 27(13):3620-3629. PubMed ID: 33883177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
    Antonia S; Goldberg SB; Balmanoukian A; Chaft JE; Sanborn RE; Gupta A; Narwal R; Steele K; Gu Y; Karakunnel JJ; Rizvi NA
    Lancet Oncol; 2016 Mar; 17(3):299-308. PubMed ID: 26858122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors.
    Patel SP; Alonso-Gordoa T; Banerjee S; Wang D; Naidoo J; Standifer NE; Palmer DC; Cheng LY; Kourtesis P; Ascierto ML; Das M; Diamond JR; Hellmann MD; Carneiro BA
    J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38309722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of the antiprogrammed cell death-1 Ab spartalizumab (PDR001) in Japanese patients with advanced malignancies.
    Minami H; Doi T; Toyoda M; Imamura Y; Kiyota N; Mitsuma A; Shimokata T; Naito Y; Matsubara N; Tajima T; Tokushige K; Ishihara K; Cameron S; Ando Y
    Cancer Sci; 2021 Feb; 112(2):725-733. PubMed ID: 33031626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase Ib/II Study of Lacnotuzumab in Combination with Spartalizumab in Patients with Advanced Malignancies.
    Ahmed J; Stephen B; Yang Y; Kwiatkowski E; Ejezie CL; Pant S
    J Immunother Precis Oncol; 2024 May; 7(2):73-81. PubMed ID: 38721402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.
    Ahn MJ; Kim DW; Cho BC; Kim SW; Lee JS; Ahn JS; Kim TM; Lin CC; Kim HR; John T; Kao S; Goldman JW; Su WC; Natale R; Rabbie S; Harrop B; Overend P; Yang Z; Yang JC
    Lancet Respir Med; 2017 Nov; 5(11):891-902. PubMed ID: 29056570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors.
    Lim EA; Bendell JC; Falchook GS; Bauer TM; Drake CG; Choe JH; George DJ; Karlix JL; Ulahannan S; Sachsenmeier KF; Russell DL; Moorthy G; Sidders BS; Pilling EA; Chen H; Hattersley MM; Das M; Kumar R; Pouliot GP; Patel MR
    Clin Cancer Res; 2022 Nov; 28(22):4871-4884. PubMed ID: 36044531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
    Arrieta O; Barrón F; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Yamamoto Ramos M; Mota-Vega B; Carmona A; Peralta Álvarez MP; Bautista Y; Aldaco F; Gerson R; Rolfo C; Rosell R
    JAMA Oncol; 2020 Jun; 6(6):856-864. PubMed ID: 32271354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies.
    Lin CC; Garralda E; Schöffski P; Hong DS; Siu LL; Martin M; Maur M; Hui R; Soo RA; Chiu J; Zhang T; Ma B; Kyi C; Tan DS; Cassier PA; Sarantopoulos J; Weickhardt A; Carvajal RD; Spratlin J; Esaki T; Rolland F; Akerley W; Deschler-Baier B; Rispoli L; Samant TS; Chowdhury NR; Gusenleitner D; Kwak EL; Askoxylakis V; De Braud F
    Oncoimmunology; 2024; 13(1):2290787. PubMed ID: 38170160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors.
    Hamid O; Chiappori AA; Thompson JA; Doi T; Hu-Lieskovan S; Eskens FALM; Ros W; Diab A; Spano JP; Rizvi NA; Wasser JS; Angevin E; Ott PA; Forgie A; Yang W; Guo C; Chou J; El-Khoueiry AB
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36302562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer.
    Gray JE; Saltos A; Tanvetyanon T; Haura EB; Creelan B; Antonia SJ; Shafique M; Zheng H; Dai W; Saller JJ; Chen Z; Tchekmedyian N; Goas K; Thapa R; Boyle TA; Chen DT; Beg AA
    Clin Cancer Res; 2019 Nov; 25(22):6623-6632. PubMed ID: 31409616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.